会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Pharmaceutical composition for use as a contraceptive
    • 用作避孕药具的药物组合物
    • US06787531B1
    • 2004-09-07
    • US09654227
    • 2000-08-31
    • Juergen HilmanWolfgang HeilRalph LippRenate HeitheckerMichael HuempelJohannes W. Tack
    • Juergen HilmanWolfgang HeilRalph LippRenate HeitheckerMichael HuempelJohannes W. Tack
    • A61K3156
    • A61K31/585A61K31/56A61K31/567A61K2300/00
    • A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
    • 作为第一活性剂的药物组合物包含对应于每日剂量的量的6β,7beta,15beta,16beta-二亚甲基-3-氧代-17α-孕-4-烯-21,17-碳内酯(屈螺酮) 在约2mg至约4mg的施用组合物上,并且作为第二活性剂,以对应于约0.01mg至约0.05mg的日剂量的量的17α-炔炔雌二醇(炔雌醇)与 一个或多个药学上可接受的载体或赋形剂。在一个具体实施方案中,组合物由多个单独包装的和单独可移除的每日剂量单位组成,放置在包装单元中并且用于口服给药至少连续21天,其中 所述日剂量单位包括屈螺酮和炔雌醇的组合。 该组合物可以进一步包含7个或更少的不含活性剂或仅含有炔雌醇的日剂量单位。